Pharmaceutical

Bristol Myers Squibb agrees to acquire RPT company RayzeBio for $4.1bn

Bristol Myers Squibb (BMS) has signed a definitive agreement for the acquisition of RayzeBio in a total equity value of nearly $4.1bn.

Dec 28, 2023 - 18:00
Bristol Myers Squibb agrees to acquire RPT company RayzeBio for $4.1bn
Bristol Myers Squibb (BMS) has signed a definitive agreement for the acquisition of RayzeBio in a total equity value of nearly $4.1bn.
Read the original article

Tags:

Previous Article

AstraZeneca buys Chinese CAR-T biotech Gracell in a $1.2bn deal

Next Article

Difficult biotech investment ecosystem forces focus on value

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA inspection underscores problem at major U.S. compounder behind hospital drug recalls

STAT+: FDA inspection underscores problem at major U.S....

Jul 26, 2023

STAT+: ‘It’s a nightmare’: One of the most common children’s asthma meds is no longer available, leaving families scrambling

STAT+: ‘It’s a nightmare’: One of the most common child...

Mar 4, 2024

Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal

Sanofi gains exclusivity rights to Ventyx’s CNS-penetra...

Sep 24, 2024